First participant receives Evategrel in CureGene’s trial

CureGene Pharmaceutical has kicked off a major U.S. pivotal clinical trial for its groundbreaking antiplatelet drug, Evategrel (CG-0255), dosing the first participant on June 20, 2026. This isn't just another clinical trial; Evategrel is a next-generation P2Y12 receptor inhibitor, the world's first available in both intravenous and oral forms, promising to revolutionize how doctors tackle cardiovascular and cerebrovascular diseases worldwide. The urgency behind Evategrel development stems from critical limitations of current antiplatelet therapies, particularly the widespread clopidogrel resistance affecting nearly 60% of East Asian patients, alongside issues of slow onset and unpredictable patient responses. Evategrel innovative thiol-hydrolyzing prodrug design bypasses the troublesome CYP450 enzyme pathway, offering ultra-rapid action (under 15 minutes for IV) and a safer profile with minimal drug interactions, making it a game-changer for emergency situations like acute ischemic stroke. The ongoing registrational trial pits Evategrel against clopidogrel across a spectrum of conditions including acute coronary syndrome, recent myocardial infarction, ischemic stroke, and peripheral arterial disease. With the U.S. pivotal trial underway, CureGene Pharmaceutical is on a fast track toward submitting its New Drug Application to the U.S. Food and Drug Administration, with regulatory approval potentially arriving as early as 2027. This development also aligns with Evategrel parallel progress in China, where a Phase II trial for ischemic stroke is in motion, underscoring CureGene's global ambition to redefine antiplatelet therapy for millions suffering from life-threatening blood clot-related conditions.